Key Points
- Alto Neuroscience CFO Nicholas Smith sold 24,056 shares for approximately $621,126 at an average price of $25.82, reducing his position by 50% to 24,060 shares. He also sold 110,830 shares the previous day for about $2.95 million.
- Alto Neuroscience shares opened at $25.22 and were down 1.2%, with the stock trading between a 12-month low of $4.04 and high of $37.48. The company recently reported a quarterly loss of $0.65 per share, beating analyst expectations.
- Analyst sentiment remains generally positive, with eight Buy ratings, two Holds and one Sell; the consensus rating is Moderate Buy with an average price target of $37.25.
Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) CFO Nicholas Smith sold 24,056 shares of the company's stock in a transaction that occurred on Wednesday, September 30th. The shares were sold at an average price of $25.82, for a total transaction of $621,125.92. Following the completion of the transaction, the chief financial officer owned 24,060 shares of the company's stock, valued at $621,229.20. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Nicholas Conrad Smith also recently made the following trade(s):
- On Tuesday, September 29th, Nicholas Smith sold 110,830 shares of Alto Neuroscience stock. The stock was sold at an average price of $26.58, for a total transaction of $2,945,861.40.
Alto Neuroscience Trading Down 1.2%
Shares of NYSE:ANRO opened at $25.22 on Friday. Alto Neuroscience, Inc. has a 12 month low of $4.04 and a 12 month high of $37.48. The company has a quick ratio of 14.85, a current ratio of 14.85 and a debt-to-equity ratio of 0.07. The company's fifty day simple moving average is $31.13 and its 200 day simple moving average is $26.15. The firm has a market cap of $989.48 million, a price-to-earnings ratio of -10.42 and a beta of 1.32.
Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.08. As a group, research analysts forecast that Alto Neuroscience, Inc. will post -2.68 EPS for the current fiscal year.
Hedge Funds Weigh In On Alto Neuroscience
Hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP increased its position in shares of Alto Neuroscience by 18.6% in the second quarter. Wellington Management Group LLP now owns 70,913 shares of the company's stock valued at $1,871,000 after acquiring an additional 11,114 shares during the last quarter. AWM Investment Company Inc. acquired a new position in Alto Neuroscience during the second quarter valued at approximately $2,111,000. Bank of New York Mellon Corp bought a new position in Alto Neuroscience in the second quarter valued at approximately $2,014,000. GK Wealth Management LLC bought a new position in Alto Neuroscience in the second quarter valued at approximately $226,000. Finally, Perceptive Advisors LLC increased its position in shares of Alto Neuroscience by 12.6% during the 1st quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company's stock worth $45,182,000 after purchasing an additional 225,500 shares during the last quarter.
Wall Street Analysts Forecast Growth
Several research analysts have recently weighed in on ANRO shares. BTIG Research upped their price objective on Alto Neuroscience from $28.00 to $37.00 and gave the stock a "buy" rating in a research report on Thursday, August 13th. Wall Street Zen cut Alto Neuroscience from a "hold" rating to a "sell" rating in a research note on Saturday, September 12th. Weiss Ratings restated a "sell (d-)" rating on shares of Alto Neuroscience in a research note on Wednesday, July 29th. HC Wainwright raised their price target on shares of Alto Neuroscience from $50.00 to $55.00 and gave the stock a "buy" rating in a research note on Monday, August 17th. Finally, Zacks Research upgraded shares of Alto Neuroscience from a "strong sell" rating to a "hold" rating in a report on Thursday, August 20th. Eight equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $37.25.
Check Out Our Latest Analysis on ANRO
Alto Neuroscience Company Profile
(
Get Free Report)
Alto Neuroscience, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for patients with psychiatric and neurological disorders. The company seeks to use neuroscience, digital health tools and biological and behavioral biomarkers to identify patient subgroups that may respond to specific treatments.
Alto's pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions. Its development programs are designed to address limitations of conventional psychiatric treatment by matching therapies to patient characteristics and measuring treatment response through objective data.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
